Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways

Shengdian Wang, Lieping Chen

Research output: Contribution to journalArticle

Abstract

Cancer immunotherapy is finally entering a new era with manipulation of cosignaling pathways as a therapeutic approach, for which the principle was proved nearly two decades ago. In addition to CTLA-4, CD137 and B7-H1/PD-1 pathways are two new targets in the stage. CD137 pathway is costimulatory and its agonistic antibody delivers potent signal to drive T cell growth and activation. On the other hand, blockade of B7-H1/PD-1 pathway with antagonistic antibody has shown to protect ongoing T cell responses from impairment by immune evasion mechanism in cancer microenvironment. With these tools in hand, a mechanism-based design of combined immunotherapy with high efficacy is becoming a reality.

Original languageEnglish (US)
Pages (from-to)245-267
Number of pages23
JournalCurrent Topics in Microbiology and Immunology
Volume344
Issue number1
DOIs
StatePublished - 2010

Fingerprint

Immunotherapy
T-Lymphocytes
Immune Evasion
Tumor Microenvironment
Antibodies
Neoplasms
Hand
Therapeutics
Growth

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology (medical)
  • Immunology
  • Microbiology

Cite this

Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways. / Wang, Shengdian; Chen, Lieping.

In: Current Topics in Microbiology and Immunology, Vol. 344, No. 1, 2010, p. 245-267.

Research output: Contribution to journalArticle

@article{45f405c6928d4b86ac9b1c88602304da,
title = "Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways",
abstract = "Cancer immunotherapy is finally entering a new era with manipulation of cosignaling pathways as a therapeutic approach, for which the principle was proved nearly two decades ago. In addition to CTLA-4, CD137 and B7-H1/PD-1 pathways are two new targets in the stage. CD137 pathway is costimulatory and its agonistic antibody delivers potent signal to drive T cell growth and activation. On the other hand, blockade of B7-H1/PD-1 pathway with antagonistic antibody has shown to protect ongoing T cell responses from impairment by immune evasion mechanism in cancer microenvironment. With these tools in hand, a mechanism-based design of combined immunotherapy with high efficacy is becoming a reality.",
author = "Shengdian Wang and Lieping Chen",
year = "2010",
doi = "10.1007/82-2010-81",
language = "English (US)",
volume = "344",
pages = "245--267",
journal = "Current Topics in Microbiology and Immunology",
issn = "0070-217X",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways

AU - Wang, Shengdian

AU - Chen, Lieping

PY - 2010

Y1 - 2010

N2 - Cancer immunotherapy is finally entering a new era with manipulation of cosignaling pathways as a therapeutic approach, for which the principle was proved nearly two decades ago. In addition to CTLA-4, CD137 and B7-H1/PD-1 pathways are two new targets in the stage. CD137 pathway is costimulatory and its agonistic antibody delivers potent signal to drive T cell growth and activation. On the other hand, blockade of B7-H1/PD-1 pathway with antagonistic antibody has shown to protect ongoing T cell responses from impairment by immune evasion mechanism in cancer microenvironment. With these tools in hand, a mechanism-based design of combined immunotherapy with high efficacy is becoming a reality.

AB - Cancer immunotherapy is finally entering a new era with manipulation of cosignaling pathways as a therapeutic approach, for which the principle was proved nearly two decades ago. In addition to CTLA-4, CD137 and B7-H1/PD-1 pathways are two new targets in the stage. CD137 pathway is costimulatory and its agonistic antibody delivers potent signal to drive T cell growth and activation. On the other hand, blockade of B7-H1/PD-1 pathway with antagonistic antibody has shown to protect ongoing T cell responses from impairment by immune evasion mechanism in cancer microenvironment. With these tools in hand, a mechanism-based design of combined immunotherapy with high efficacy is becoming a reality.

UR - http://www.scopus.com/inward/record.url?scp=79960267154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960267154&partnerID=8YFLogxK

U2 - 10.1007/82-2010-81

DO - 10.1007/82-2010-81

M3 - Article

VL - 344

SP - 245

EP - 267

JO - Current Topics in Microbiology and Immunology

JF - Current Topics in Microbiology and Immunology

SN - 0070-217X

IS - 1

ER -